Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaGünter U. Höglinger, Yaroslau Compta, Jean‐Christophe Corvol et al.|Movement Disorders|2017Cited by 2.3k
At the interface of sensory and motor dysfunctions and Alzheimer's diseaseMark W. Albers, Li I. Zhang, Grover C. Gilmore et al.|Alzheimer s & Dementia|2014Cited by 594
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's diseaseOskar Hansson, Charlotte E. Teunissen, Rebecca M. Edelmayer et al.|Alzheimer s & Dementia|2022Cited by 589
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trialsAdam L. Boxer, Reisa A. Sperling|Cell|2023Cited by 181
Apolipoprotein E ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementiaFederica Agosta, Maria Luisa Gorno‐Tempini, Bruce L. Miller et al.|Proceedings of the National Academy of Sciences|2009Cited by 180